Sustained Changes of Treg and Th17 Cells During Interferon-α Therapy in Patients with Chronic Hepatitis B.
Chronic hepatitis B (CHB) is a worldwide infectious disease caused by hepatitis B virus (HBV). HBV mainly damages liver cells through immune response. The purpose of this study was to determine whether there were dynamic changes of Treg and Th17 cells and to judge the value of these indicators to antiviral treatment. Twenty-two CHB patients and selected 30 healthy adults were enrolled. Results showed that the expression of Treg (5.72±0.46 vs. 4.42±0.17, p=0.0019) and Th17 (3.94±0.64 vs. 2.66±3.12, p=0.0436) cells was significantly increased in CHB patients, as well as the level of interleukin-17 (IL-17) (16.88±5.37 vs. 8.59±3.31; p=0.004). Then, we monitored longitudinally the impact of the treatment with interferon-α and found that the suppression of viral replication induced by interferon-α resulted in a decrease in Treg, Th17 cells, and IL-17; we also found that the percentage of Treg and Th17 cells went up without clear evidence of clinical autoimmune disease at the end of treatment. Thus, Treg and Th17 cells might play an important role in interferon-α treatment to eliminate HBV. The level of changes may be served to determine the antiviral efficacy of interferon-α therapy.
1 Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, First Clinical Medical College of Nanjing Medical University , Nanjing, China .|2 Nanjing Jiangbei People's Hospital , Nanjing, China .
Hao
H
Feng
2 Nanjing Jiangbei People's Hospital , Nanjing, China .
Jie
J
Yin
1 Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, First Clinical Medical College of Nanjing Medical University , Nanjing, China .
Ya-Ping
YP
Han
1 Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, First Clinical Medical College of Nanjing Medical University , Nanjing, China .
Xiao-Ying
XY
Zhou
2 Nanjing Jiangbei People's Hospital , Nanjing, China .
Su
S
Chen
2 Nanjing Jiangbei People's Hospital , Nanjing, China .
Li
L
Yang
2 Nanjing Jiangbei People's Hospital , Nanjing, China .
Jin-Rui
JR
Yan
1 Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, First Clinical Medical College of Nanjing Medical University , Nanjing, China .
Guo-Xin
GX
Zhang
D000328:Adult; D004279:DNA, Viral / Q000097:blood; D016903:Drug Monitoring; D005260:Female; D005434:Flow Cytometry; D019694:Hepatitis B, Chronic / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D020381:Interleukin-17 / Q000032:analysis; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D058504:Th17 Cells / Q000276:immunology*; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult
D004279:DNA, Viral; D016898:Interferon-alpha; D020381:Interleukin-17